Investment Rating - The report provides a comprehensive valuation table for various companies in the building materials industry, indicating a range of price-to-earnings (PE) and price-to-book (PB) ratios for 2025E and 2026E [1] Core Insights - The report highlights the expected growth in net profit for several companies, with notable increases such as 90 million CNY for Conch Cement in 2025E and 100 million CNY in 2026E, reflecting a strong market position [1] - The PE ratios for the companies vary significantly, with Conch Cement at 15.3 for 2025E and 13.8 for 2026E, while companies like Jidong Cement show a much higher PE of 37.2 for 2025E [1] - The report emphasizes the valuation metrics, with companies like China National Building Material having a low PB ratio of 0.34, indicating potential undervaluation [1] Summary by Category Cement - Conch Cement has a total market value of 138.1 billion CNY, with projected net profits of 90 million CNY in 2025E and 100 million CNY in 2026E, and a PE of 15.3 for 2025E [1] - Huaxin Cement is valued at 31.9 billion CNY, with net profits expected to reach 25 million CNY in 2025E and 30 million CNY in 2026E, showing a PE of 12.7 for 2025E [1] - Other notable companies include Tianshan Shares with a market value of 43.1 billion CNY and projected net profits of 15 million CNY in 2025E [1] Consumer Building Materials - Rabbit Baby is projected to have net profits of 7.5 million CNY in 2025E and 8.5 million CNY in 2026E, with a PE of 11.2 for 2025E [1] - China Liansu is valued at 14.5 billion CNY, with expected net profits of 22 million CNY in 2025E and 24 million CNY in 2026E, showing a low PE of 6.6 for 2025E [1] Glass and Fiberglass - Shandong Pharmaceutical Glass has a market value of 15.1 billion CNY, with projected net profits of 10.5 million CNY in 2025E and 11.5 million CNY in 2026E, and a PE of 14.3 for 2025E [1] - China Jushi is valued at 51.5 billion CNY, with net profits expected to reach 35 million CNY in 2025E and 40 million CNY in 2026E, showing a PE of 14.7 for 2025E [1] New Materials - Zhongfu Shenying has a market value of 19.3 billion CNY, with projected net profits of 0.5 million CNY in 2025E and 1.5 million CNY in 2026E, reflecting a very high PE of 385.0 for 2025E [1] - Jilin Carbon Valley is valued at 8.5 billion CNY, with expected net profits of 1 million CNY in 2025E and 1.3 million CNY in 2026E, showing a PE of 85.0 for 2025E [1]

Core Insights - The molded bottle market holds a significant share in the borosilicate glass segment, accounting for approximately 44% of the market in 2024 [1] - The market for borosilicate ampoules is projected to grow from 600 million yuan in 2018 to 2.5 billion yuan in 2024 [2] - The market for neutral borosilicate molded bottles is expected to increase from 900 million yuan in 2018 to 3.8 billion yuan in 2024 [5] - The market for neutral borosilicate tubular bottles (excluding ampoules) is anticipated to grow from 600 million yuan in 2018 to 2.3 billion yuan in 2024 [6] - The strategic positioning of the borosilicate glass market indicates that neutral borosilicate molded bottles and ampoules are "star markets" with high growth potential and strong competitive positions [8] Market Analysis - The molded bottle segment is the largest within the borosilicate glass market, highlighting its importance in the pharmaceutical packaging industry [1] - The growth trajectory of the borosilicate ampoule market reflects increasing demand, with a substantial rise in market size over the years [2] - The neutral borosilicate molded bottle market is also experiencing significant growth, indicating a robust demand for this type of packaging [5] - The neutral borosilicate tubular bottle market, while growing, is currently positioned with moderate demand potential and competition [6] - The analysis using the Boston Matrix framework suggests that the borosilicate glass industry has promising segments that could attract investment and development [8]

Investment Rating - The investment rating for the construction materials industry is "Positive" (maintained) [1] Core Views - The central urban work conference emphasized urban renewal, which is expected to drive demand for construction materials such as pipes, waterproofing, and coatings. This will lead to significant improvements in the real estate chain's fundamentals [3] - The report recommends several companies in the consumer building materials sector, including Sankeshu (channel expansion), Dongfang Yuhong (waterproofing leader), Weixing New Materials (high retail business ratio), and Jianlang Hardware. Beneficiary companies include Beixin Building Materials (gypsum board leader) [3] - The National Development and Reform Commission's action plan for the cement industry aims to control cement clinker capacity at around 1.8 billion tons by the end of 2025, which is expected to accelerate energy-saving and carbon reduction efforts [3] Market Performance - The construction materials index fell by 0.23% in the week from July 14 to July 18, 2025, underperforming the CSI 300 index by 1.32 percentage points. Over the past three months, the CSI 300 index rose by 7.17%, while the construction materials index increased by 4.36%, underperforming by 2.82 percentage points. In the past year, the CSI 300 index rose by 14.68%, and the construction materials index increased by 16.62%, outperforming by 1.94 percentage points [4][13] Cement Sector - As of July 18, 2025, the average price of P.O42.5 bulk cement nationwide was 280.87 CNY/ton, down 0.71% month-on-month. The clinker inventory ratio was 67.24%, up 1.35 percentage points [6][27] - The report highlights regional price variations, with Northeast China stable, North China up by 0.74%, and East China down by 1.90% [26] Glass Sector - The spot price of float glass as of July 18, 2025, was 1214.63 CNY/ton, an increase of 0.71% from the previous week. The inventory of float glass nationwide decreased by 175 million weight boxes, a decline of 3.05% [82][84] - The average price of photovoltaic glass remained stable at 116.02 CNY/weight box [89] Fiberglass Sector - The market price for non-alkali 2400tex direct yarn ranged from 3300 to 4100 CNY/ton, with variations depending on the manufacturer [6] Consumer Building Materials - As of July 18, 2025, the price of asphalt was 4570 CNY/ton, stable week-on-week, and up 2.93% year-to-date. The price of titanium dioxide was 13050 CNY/ton, down 1.14% month-on-month [6]

Core Viewpoint - The acquisition of Shandong Luzhong Investment Co., Ltd. by China International Pharmaceutical Co., Ltd. and its Hong Kong counterpart is under review by the State Administration for Market Regulation, indicating a significant shift in control within the pharmaceutical packaging industry in China [2][3]. Group 1: Acquisition Details - China International Pharmaceutical Co., Ltd. and its Hong Kong subsidiary will increase their stake in Shandong Luzhong Investment, which specializes in pharmaceutical packaging, with the new ownership structure resulting in a joint control arrangement [2]. - Post-acquisition, China International will hold 36% and China International Hong Kong will hold 15% of Luzhong Investment, while Luzhong Holdings will retain 49% [2]. - The ultimate controller of both China International and its Hong Kong subsidiary is China National Pharmaceutical Group, which will indirectly hold 51% of Luzhong Investment after the transaction [2]. Group 2: Impact on Related Companies - Following the completion of the equity change, the indirect controlling shareholder of Shandong Pharmaceutical Glass Co., Ltd. will shift from Luzhong Holdings to China International, with the actual controller changing from the Yiyuan County Finance Bureau to China National Pharmaceutical Group [4]. - China International will consolidate Luzhong Investment into its financial statements and will indirectly hold 19.5% of Shandong Pharmaceutical Glass through Luzhong Investment, making it the indirect controlling shareholder [4]. Group 3: Company Performance - Shandong Pharmaceutical Glass, established in 1970 and listed in 2002, has developed a comprehensive product system in the pharmaceutical packaging industry [6]. - The latest annual report indicates a revenue of 5.125 billion yuan for 2024, a year-on-year increase of 2.87%, and a net profit of 943 million yuan, reflecting a growth of 21.55% [6]. - The company's stock price as of July 18 was 22.59 yuan, with a market capitalization of approximately 14.991 billion yuan and a TTM P/E ratio of 15.85 [7].

Core Insights - The investment enthusiasm for borosilicate glass production capacity in China is moderate, with companies like Linuo Pharmaceutical starting production with significant investments but requiring time for ramp-up [1][2] - The overall production capacity for borosilicate glass is sufficient, with major players like Shandong Pharmaceutical Glass and Linuo Pharmaceutical planning substantial increases in capacity by 2025 [2][4] - The production of borosilicate glass is generally on the rise, although some companies are experiencing declines in specific product lines [5] - Sales of borosilicate glass are declining across the industry, with most leading companies reporting lower sales figures compared to the previous year [6] - The overall production and sales rates for borosilicate glass companies are below 100%, indicating inefficiencies in the market [7][9] Production Capacity - Linuo Pharmaceutical's production capacity for borosilicate medicinal molded bottles is approximately 5,081 tons, with plans to increase capacity by an additional 46,574 tons by 2025 [4] - Shandong Pharmaceutical Glass will achieve a production capacity of 170,000 tons for molded bottles upon completion of its project [2][4] - Other companies like Shandong Dingxin and Kaisen Junheng are also expanding their production capabilities significantly [4] Production and Sales Trends - Linuo Pharmaceutical's production is expected to increase by 25.78% in 2024 compared to 2023, while other companies like Zhengchuan Co. are seeing a decrease in production [5] - Sales figures for borosilicate glass are generally declining, with Linuo Pharmaceutical showing a 20.57% increase in sales, while others like Zhengchuan Co. report a 15.87% decrease [6] - The production and sales rates for major companies are mostly below 100%, indicating potential overcapacity or inefficiencies [7][9]

Summary of Conference Call Records Industry Overview - The conference call primarily discusses the **consumption building materials industry** and its performance in 2024, highlighting a **7.2% year-on-year decline** in revenue for the sector [1] - The **real estate demand** remains weak, impacting the consumption building materials sector, which has seen continuous revenue pressure over the past few quarters [1] Key Points and Arguments - **Revenue Trends**: The revenue growth for the consumption building materials sector is expected to decline in 2024, with quarterly comparisons showing fluctuations: **0.2% growth**, **5.3% decline**, **10.7% decline**, **10.9% decline**, and **5.7% decline** from Q1 2024 to Q1 2025 [1] - **Profitability Issues**: The industry faces challenges such as **declining gross margins** due to reduced demand and increased expense ratios. Some companies have reported increased impairments on goodwill and assets [2] - **Improvement in Profitability**: In Q1 2024, some companies managed to stabilize and improve profitability through better gross margins and expense control, with half of the consumption building materials companies reporting year-on-year gross margin increases [2] - **Net Profit Performance**: Among 26 analyzed companies, **10 reported year-on-year net profit increases**, and **9 showed improvements in net profit margins** both year-on-year and quarter-on-quarter, particularly in waterproofing and coating sectors [3] - **Market Resilience**: Despite the downturn in new housing demand, the sector shows resilience supported by the high demand for second-hand housing, which could lead to revenue growth if new housing demand stabilizes [4] Additional Insights - **Future Growth Potential**: Companies with strong brand and channel capabilities are expected to have significant growth potential. Key players mentioned include **Sanhe Tree, Tubaobao, Beixing Building Materials, and others** [5] - **Cement Industry Outlook**: The cement sector is projected to see a bottoming out in Q1 2024, with expectations of gradual improvement in profitability throughout the year. The industry experienced a **35% year-on-year decline** in scale in 2024 [5] - **Price Trends**: Cement prices are expected to rise after a period of decline, with a **1.4% year-on-year drop** in demand noted in Q1 2024, but a recovery is anticipated post-Chinese New Year [6] - **Cost Management**: The decline in coal prices is expected to stabilize industry profitability, with a projected **6% year-on-year decline** in cement demand for 2025 [7] - **Investment and Dividends**: Companies with low cash flow and stable investment returns, such as **Tapai Group and Ningxia Building Materials**, are highlighted for their significant profit contributions [8] Conclusion - The consumption building materials and cement industries are navigating through challenging market conditions, with signs of potential recovery in profitability and demand stabilization. Key players are expected to leverage their market positions for future growth opportunities.

Investment Rating - The investment rating for the construction materials industry is "Positive" (maintained) [1] Core Views - The Ministry of Housing and Urban-Rural Development emphasizes the importance of stabilizing the real estate market, which is expected to lead to significant improvements in the fundamentals of the real estate chain. Recommended stocks in the consumer building materials sector include Sankeshu, Dongfang Yuhong, Weixing New Materials, and Jianlang Hardware. Beneficiary stocks include Beixin Building Materials [3] - The National Development and Reform Commission has issued a special action plan for energy conservation and carbon reduction in the cement industry, aiming to control cement clinker capacity at around 1.8 billion tons by the end of 2025, with a target of reducing comprehensive energy consumption per unit product by 3.7% compared to 2020 [3] - The "equal tariff" policy is expected to benefit fiberglass leaders with overseas production bases, allowing them to raise prices and consolidate profitability [3] Market Performance - The construction materials index rose by 3.34% in the week from July 7 to July 11, 2025, outperforming the CSI 300 index by 2.52 percentage points. Over the past three months, the CSI 300 index increased by 6.41%, while the construction materials index rose by 6.60%, indicating a slight outperformance of 0.18 percentage points [4][13] - In the past year, the CSI 300 index increased by 15.62%, and the construction materials index rose by 15.80%, also showing a slight outperformance of 0.18 percentage points [4][13] Cement Sector - As of July 11, 2025, the average price of P.O42.5 bulk cement nationwide was 282.89 CNY/ton, a decrease of 3.48% month-on-month. The clinker inventory ratio was 65.89%, down 2.29 percentage points [6][23][24] - The price of cement varied by region, with notable declines in Northeast (-4.76%), North China (-2.33%), East China (-2.98%), South China (-5.74%), Central China (-3.41%), and Southwest (-4.93%) regions [23][29] Glass Sector - The average price of float glass as of July 11, 2025, was 1205.63 CNY/ton, with a slight increase of 0.17%. The average price of photovoltaic glass remained stable at 116.02 CNY/weight box [6][71][78] - The inventory of float glass decreased by 970,000 weight boxes nationwide, a decline of 1.66% [73][74] Fiberglass Sector - The price of non-alkali 2400tex direct yarn ranged from 3400 to 4100 CNY/ton, with flexible pricing based on regional differences [6] Consumer Building Materials - As of July 11, 2025, the price of crude oil was 70.63 USD/barrel, down 0.39% week-on-week. The price of asphalt was 4570 CNY/ton, up 1.11% week-on-week [6]

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a slight increase of 0.39% recently, reflecting the overall performance of listed companies in the healthcare sector [1] Group 1: Index Performance - The China Securities Index for Healthcare Equipment and Services is currently at 13,682.83 points with a trading volume of 18.089 billion [1] - Over the past month, the index has decreased by 0.83%, while it has increased by 2.95% over the last three months, and has seen a year-to-date decline of 0.43% [1] Group 2: Index Composition - The index is composed of listed companies that correspond to the healthcare theme, with a base date of December 31, 2004, set at 1,000.0 points [1] - The top ten weighted companies in the index include: Mindray Medical (9.44%), United Imaging (8.04%), Aier Eye Hospital (7.55%), Aimeike (3.41%), Huatai Medical (3.23%), New Industry (2.81%), Yuyue Medical (2.7%), Lepu Medical (2.54%), Meinian Onehealth (2.05%), and Shandong Pharmaceutical Glass (1.91%) [1] Group 3: Market Distribution - The index's holdings are primarily listed on the Shenzhen Stock Exchange (60.09%) and the Shanghai Stock Exchange (39.91%) [1] - The healthcare sector accounts for 100% of the index's holdings [1] Group 4: Index Adjustment and Fund Tracking - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2] - Public funds tracking the healthcare index include various Southern and Tianhong funds, as well as ETFs from multiple financial institutions [2]

Group 1: ETF Performance and Liquidity - The biopharmaceutical vaccine ETF has a turnover rate of 1.9% during trading, with a transaction volume of 4.8922 million yuan [3] - Over the past two weeks, the biopharmaceutical vaccine ETF has seen a scale increase of 8.7844 million yuan, ranking first among comparable funds [3] - As of July 10, the biopharmaceutical vaccine ETF has achieved a net value increase of 22.89% over the past year [3] - The ETF's highest monthly return since inception is 26.27%, with the longest consecutive monthly gain being 3 months and the longest gain percentage being 14.87% [3] - The average return during the months of increase is 6.41% [3] Group 2: Index Valuation and Composition - The index tracked by the ETF, the CSI Vaccine and Biotechnology Index, is currently valued at a historical low, with a price-to-book ratio (PB) of 2.6 times, which is lower than 88.03% of the time over the past three years, indicating strong valuation attractiveness [3] - The CSI Vaccine and Biotechnology Index includes no more than 50 companies involved in vaccine research, production, and related biotechnology sectors, reflecting the overall performance of listed companies in this theme [3] Group 3: Major Stocks and Market Trends - As of June 30, 2025, the top ten weighted stocks in the CSI Vaccine and Biotechnology Index include Zhifei Biological Products, Wantai Biological Pharmacy, Watson Bio, and others, collectively accounting for 48.14% of the index [4] - The top weighted stocks and their respective weights are: Zhifei Biological (10.06%), Wantai Biological (8.43%), Watson Bio (6.19%), and others [6] - On July 8, the National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, proposing 16 supportive policies [6] Group 4: International Market Opportunities - Institutions are focusing on the opportunities for Chinese vaccines in international markets under the "World Shared Market" concept, particularly in Belt and Road countries [7] - Chinese vaccines are expected to leverage cost advantages to expand into the pharmaceutical markets of Belt and Road countries, especially in light of supply chain risks faced by non-U.S. countries [7] - The vaccine market is sensitive to population variables, and Chinese companies have established production capacity and distribution channels in Belt and Road countries, laying a solid foundation for international expansion [7]

Group 1 - The global borosilicate glass industry has entered a high-quality development stage, driven by its importance in laboratories, industrial applications, and household products [1] - The demand for borosilicate glass is expanding due to its applications in various products such as thermometers, lamp shades, syringes, and baby bottles [1] Group 2 - The global borosilicate glass market is projected to reach approximately $4.4 billion by 2024, with a year-on-year growth of 4.6% [3] - The North American region is currently the largest market for borosilicate glass, accounting for nearly half of the global market share [4] Group 3 - By 2030, the global borosilicate glass market is expected to grow to $6.5 billion, benefiting from the development of the global pharmaceutical market and increased penetration in developing countries [6] Group 4 - Key trends in the global borosilicate glass industry include the growing importance of emerging markets, the need for sustainable development, and continuous improvement in production processes [10] - Emerging markets are expected to play a significant role in the growth of the borosilicate glass market due to urbanization and rising income levels [10] - Companies are facing stricter environmental regulations and need to invest in cleaner production methods to reduce waste emissions [10] - Industry leaders are innovating production techniques to enhance efficiency and product quality, utilizing advanced technologies such as AI and big data [10]